Reviva Pharmaceuticals

Reviva Pharmaceuticals
We are a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.
Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house using our chemical genomics driven technology platform.

Brilaroxazine: The Potential Future Standard of Care for Schizophrenia
Our lead drug candidate, brilaroxazine, is in clinical development for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder, major depressive disorder (MDD), behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD). Our primary focus is to complete the clinical development of brilaroxazine for the treatment of acute and maintenance schizophrenia.